Matrix metalloproteinases in multiple sclerosis: Is it time for a treatment trial?
- 8 October 2001
- journal article
- editorial
- Published by Wiley in Annals of Neurology
- Vol. 50 (4) , 431-433
- https://doi.org/10.1002/ana.1236
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon‐β therapy in relapsing and secondary‐progressive multiple sclerosis patientsAnnals of Neurology, 2001
- Multiple SclerosisNew England Journal of Medicine, 2000
- Changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MSNeurology, 1999
- Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosisBrain, 1999
- Interferon β‐1b decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase‐9Annals of Neurology, 1996
- Matrix metalloproteinases degrade myelin basic proteinNeuroscience Letters, 1995
- Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases.Journal of Clinical Investigation, 1994
- Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disordersJournal of Neuroimmunology, 1992
- TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenaseBrain Research, 1992
- XVIII.–The Histology of Disseminated SclerosisTransactions of the Royal Society of Edinburgh, 1916